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Abstract
Adherence to antiretroviral therapy (ART) is essential to achieving an improved cluster of
differentiation-4 (CD4) count, viral load, and quality of life while preventing drug resistance.
Medication adherence among people living with Human Immunodeficiency Virus (HIV) is
influenced by different factors. Several studies have identified adherence promoters and
inhibitors that emanate from the internal and external environment. We conducted six (6)
individual in-depth interviews and three (3) focus group discussions to explore adherence
behaviour among patients diagnosed with HIV in a teaching hospital in Accra, Ghana. Par-
ticipants were drawn from the intervention arm of a mobile phone adherence intervention
program. They had been enrolled in the study for at least six (6) months before the inter-
views are conducted. Results revealed that participants adhered to treatment irrespective of
prompts from significant others. Adherence promoters included perception of ART as part of
daily routines, benefits of the ART, awareness of regimen, access to food, and transpar-
ency. Adherence inhibitors were forgetfulness, secrecy, waiting time, religious beliefs, and
sleep. People living with HIV (PLWHIV) have the personal motivation to take medication;
however, negative perceptions about HIV must be addressed to ensure optimum adherence
behaviour.
Introduction
The Joint United Nations Programme on Human Immunodeficiency Virus (HIV)/Acquired
Immune Deficiency Syndrome (AIDS) (UNAIDS) and World Health Organization (WHO)
projected that about 36.9 million people were living with HIV, while 1.8 million were newly
diagnosed as of 2017 [1,2]. Globally, HIV mortality has declined from 1.5 million in 2000 to
0.9 million in 2017, while treatment access and coverage have increased (2 million in 2000 to
21.7 million in 2017) with an estimated 59% of patients receiving treatment. However, the
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debilitating effect of HIV is still evident in Africa. About 53% of all persons living with HIV
reside in Sub-Saharan Africa. Despite these high incidences, treatment coverage and access
(15,358,000; 60%) have contributed to mortality declining by 35% compared with the year
2000 estimates.
The adult prevalence rate of HIV in Ghana in 2018 was 1.7%, with 20,000 new cases and
14,000 deaths recorded [2]. A notably low treatment access rate of 40% was recorded relative
to global and regional averages. In the face of these gaps in access to HIV treatment, the impor-
tance of adherence behaviour in ensuring improvement in outcomes cannot be dismissed.
Consequently, adherence monitoring is included as one of the pillars within the treatment
modalities of HIV care.
Adherence to antiretroviral drugs (ARVs) is a major facilitator for improving the outcome
of care for people living with HIV (PLWHIV). It promotes treatment effectiveness and mini-
mises adherence-related drug resistance [1]. The consequence of non-adherence behaviour is
associated with ineffective treatment, delayed remission of illness, drug resistance, prolonged
or recurrent hospitalization, increased treatment cost, and a higher risk of death [3]. Further-
more, PLWHIV who have high viral loads and do not adhere to treatment are more likely to
infect others, which increases HIV incidence rates and burden of care on the health systems.
Despite the fact that optimum antiretroviral therapy (ART) adherence for some antiretroviral
treatment is attained at 95% level of adherence [3], adherence behaviour levels, its outcome,
and associated meaning may vary in different populations globally. Ortego, Huedo-Medina
[4] in a meta-analysis compared the levels of adherence between male and female respondents
and observed a 90% level of adherence in about 62% of patients receiving treatment. Levels of
adherence among patients in parts of Ghana were also estimated to span from 73.6% to 91%
[5].
Initiating ART, sustaining the treatment, and dealing with the associated biopsychosocial
outcomes remains a challenge. Measures were introduced to reduce medication sideeffects,
pills burden, and the dosing frequency, were identified as barriers to medication adherence.
However, issues relating to the decision-making process in treatment adherence still persist.
Factors influencing adherence manifest as either promoters or inhibitors of adherence
behaviour. Previous studies have suggested that PLWHIV are motivated to take treatment
depending on the premium they place on the treatment, the benefits, self-efficacy, acceptance
of diagnosis, and disclosure of status [6–9].
Adherence behaviour is linked to the importance of the medication and the benefits derived
from taking the ART. Patients who experience an improvement in their health status as a result
of medical care and adherence to treatment may become motivated to take medication volun-
tarily [10]. Starks et al. [9] conducted an in-depth study with 29 participants in Beijing and
observed that patients’ will to live promoted adherence behaviour. Similarly, van Loggerenberg
[10] mentioned that ART was perceived as a lifesaver among most patients in South Africa,
hence, encouraged adherence behaviour.
Adherence is also better among patients with the knowledge, skills, and attitude that
ensures consistency with medication schedules [11]. The adherence counselling session
empowers patients to be conscious of the relevance of the ART and the long-term obligation
[12]. Chung et al. [12] implemented adherence counselling sessions lasting at least 30 minutes.
Trained counsellors in Kenya provided two (2) counselling sessions to patients before initiat-
ing treatment and a third session a month after treatment was started. They evaluated phar-
macy replenishment records and patients’ virology status in the study. The outcome supported
the effectiveness of counselling in promoting adherence behaviour, which contributed to the
positive care outcomes for the patients. They further noted non-compliance with intention-to-
treat analysis—a technique used in randomised control trials as a limitation. An in-depth
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report would have accounted for what led to the success of the counselling sessions. Nonethe-
less, patients’ adherent behaviour depends on the response to diagnosis and willingness to dis-
close status.
Patients’ acceptance of diagnosis and willingness to disclose status enhances social support,
thereby facilitating adherence. Accepting diagnosis ensures prompt initiation of treatment,
while denial leads to delay and poor health outcomes [11]. Portelli [11] affirmed this stance
and noted that HIV status disclosure promoted support from relations, companions, and sig-
nificant others. The contrary case is that fear of stigma leads to the patient’s failure to disclose
HIV positive status, which results in inadequate support from their significant others [11]. Lit-
erature suggests that patients need support to remember their medication schedule and
appointments but this would be feasible only when information about their status is disclosed.
Forgetting to take pills has been reported widely as a major barrier to treatment adherence
in patients receiving ART [11,13]. Other patient-related factors contributing to non-adherence
to ART include depression, stigma [7,11,14], lack of self-worth, age, low health literacy levels,
preference for alternative treatment, denial of HIV status, limited financial resources, and cog-
nitive impairment [7].
In view of the seeming contextual differences, we posed the following questions: What is
the adherence behaviour among PLWHIV in Ghana? What factors support positive adherence
outcomes? Why do some patients stop or miss taking their medication?
Materials and methods
This was a phenomenological qualitative study. We conducted six (6) in-depth interviews and
three (3) focus groups (20 participants) as part of Phase Three (3) of an intervention study that
implemented an integrated mobile phone intervention. Participants in the intervention group
of the two-arm randomized control trial were supported to set mobile phone alarms on medi-
cation time. Additionally, they received weekly text messages and monthly voice calls. Partici-
pants were assessed at baseline, then again at three and six months. Participants in the
intervention group were purposively selected for in-depth interviews and focus groups in the
sixth month. This enabled the researchers to elicit their experiences prior to the intervention
and their evaluation of the integrated mobile phone intervention.
Adult participants (between 18–65 years of age) who were receiving ART in a teaching hos-
pital in Accra, Ghana were recruited from February 2015 to April 2015 using purposive sam-
pling. Thirty (30) out of 181 participants who met the inclusion criteria were invited to take
part in the interview and focus group discussions. Twenty-six (26) accepted and were inter-
viewed. The remaining four (4) participants were not available to be interviewed. The sample
size for the interview was determined by data saturation–which is the point at which no new
or additional ideas were being identified in the interviews. Participation included: use of
alarms for medication adherence, receipt of weekly text messages and monthly voice calls for
the six (6) months duration of the intervention. Participants in the intervention group who did
not set alarms to monitor their medication or receive weekly messages and monthly voice calls
were excluded from the interview phase.
The principal investigator (GD) and three (3) trained research assistants conducted the inter-
views with interview guides through face-to-face interaction with participants. Only the
research assistants were present during individual interviews and focus group discussions. The
interviewers’ familiarity and prior engagement with the participants facilitated an open discus-
sion of sensitive issues that would not have been discussed if there was no relationship. The
research assistants’ initial interviews were done with the principal investigator following the
training until the principal investigator was satisfied with the interviewing skill of the volunteer.
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Satisfaction with the volunteer’s interviewing skills was based on the ability to take participants’
informed consent correctly, pose questions on the interview guide, and probe participants’
responses. Interviews were scheduled to coincide with participants’ regular clinic visits. A pri-
vate room in the hospital was secured for the interviews. Participants’ written informed consent
was sought for the interview, audio recording, and use of data. Code names were assigned to
each participant to protect their privacy on the audio recordings. Questions and probes on the
interview guide were used relative to the responses of the participants and study objectives.
Additionally, field notes were taken to guide the interpretation of data. Each interview
lasted for about 30 minutes while the focus group discussions lasted for at least 60 minutes.
The qualitative data collection lasted for a period of three (3) months (February to April 2015).
No repeat interviews were conducted. We were unable to register the trial at the time of com-
mencement; although, the protocol was submitted due to funding requirement. There was,
however, rigorous review and monitoring by a three (3) member steering committee who
managed the entire process. Written ethical clearance was obtained from the Noguchi Memo-
rial Institute for Medical Research Institutional Review Board (NMIMR-IRB) (Approval Num-
ber: 039/13-14). With the aid of the study’s information sheet, the interviewers explained the
study’s purpose, duration, and participants’ roles to them. The right to enroll, decline, or with-
draw from the study was also explained and enforced. Participants received incentives in the
form of transportation, mobile phone call credits, and snacks. This study adheres to the Con-
solidated Criteria for Reporting Qualitative Studies (COREQ) [15].
Data analysis
We used Tesch’s [16] comprehensive guidelines for transcribing and analysing in-depth inter-
view data, as reported by Creswell [17]. This involves describing, classifying, and connecting the
elements of the data. The eight (8) specific steps were: transcription, extracting codes, clustering
data, categorising, exhaustive description of data, category labelling, category, grouping category
and description. We transcribed audio recordings verbatim and read the transcripts several times
to make meaning of data. Each interview and focus group discussions transcript were uploaded
into ATLAS Ti 7 software as separate files for coding. The codes were discussed among team
members (n = 3); then clustering, categorising, and grouping of the code into themes and sub-
themes was completed. The themes and subthemes generated from the data were described in
detail with direct quotes supporting the various categories. Although the interviews and focus
groups were analysed separately, the data were discussed and integrated into the study findings.
The focus groups were done to validate and provide additional information. Field notes were
integrated into the findings to reflect the context of the narratives. No transcripts were returned
to participants for comments or correction but clarity was sought during focus group discussions
on aspects requiring more probing. The participants verified the findings verbally.
We ensured that data were credible by using various approaches in data collection, such as
focus group discussions, face-to-face interviews, field observations, and document reviews.
Although the interviewers had experiences in HIV care, biases were limited through reflexivity.
The findings were verified through member checking. The findings have been reported with
relevant details to facilitate transferability without compromising the privacy and confidential-
ity of participants. Participation was voluntary and participants’ privacy was ensured in line
with the tenets of research ethics.
Results
ART is a long-term treatment and requires lifetime commitment and consistency. Individuals
taking ART may be either adherent or non-adherent to treatment. Participants reported their
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motivation for adhering to treatment and circumstances under which non-adherence
occurred. Adherence behaviour from the participants’ perspective was influenced mostly by
advice on diet, substance abuse, and meeting follow-up visit schedules.
The two (2) main themes derived were adherence promoters and adherence inhibitors. The
subthemes for adherence promoters were: adherence to antiretroviral therapy as a routine,
familiarity with medication regimen, benefits of ART, access to food, fear of death, pill mobil-
ity, status disclosure and voice calls. The subthemes for adherence inhibitors were: forgetful-
ness, religious beliefs, nondisclosure (secrecy), waiting time, and sleeping. The initials (FDG)
were used to represent data extracts from focus group interviews while (P) represented indi-
vidual interviews. Quotations from focus groups 1, 2 and 3 were designated as (FDG 1), (FDG
2) and (FDG 3), respectively.
The participants’ demographic characteristics are summarized in Table 1.
Adherence behaviour promoters
Participants acknowledged that they adhered to treatment as a routine and because of the ben-
efits derived. They also noted that food played an important role in adhering to treatment
since it reduced the undesired side effects of ARVs, such as weakness and dizziness. The partic-
ipants mentioned that fear of death heightened the willingness to strictly follow the treatment
regimen. Other participants indicated that they carried their pills with them to avoid missing
or delaying medication time. In evaluating the intervention, voice calls were the preferred
adherence support measure.
Adherence to antiretroviral therapy as a routine. Some participants revealed that strictly
following their medication regimen was part of their daily routine. This was because they had
been on the ARV treatment for over five (5) years; thus, taking the medication had become a
Table 1. Socio-demographic characteristics of study participants.
Individual Interviews Focus Group 1 Focus Group 2 Focus
Group 3
Total
Age Mean (SD) 37(7.52) 41(1.86) 38(6.85) 47(5.81) 41(7.28)
Gender
Male 3 2 6 5 14
Female 3 4 2 1 14
Education
Tertiary 1 1 0 0 4
Below tertiary 4 0 2 2 8
No education 1 5 6 4 16
Relationship
Married 5 6 4 4 21
Not married 1 0 4 2 7
Children
None 2 0 5 0 7
2 or less 4 5 2 3
3 or more 0 1 1 3 5
Duration of illness
Mean (SD) 3(1.72) 4(2.14) 2(2.27) 5(2.58) 6(2.58)
Treatment duration
Mean (SD) 2(1.72) 3(1.86) 2(1.69) 4(1.72) 5(1.85)
Total participants 6 6 8 6 26
https://doi.org/10.1371/journal.pone.0230159.t001
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well-established routine. More so, participants appreciated the consequences of non-adher-
ence, such as treatment failure, and poor health status, which therefore challenged them to
adhere to their medication regimen.
As for the medicine, when you take it for some time you become used to it such that you do
not need anyone to remind you to take it. . .I have followed exactly as I was taught during the
counselling sessions to the extent that I have to run for my drugs when the time passes by a sec-
ond. I always want to take the drugs on time so that I will be strong at all times. . ..during
counselling we were informed and cautioned about the need to stick to the medication as pre-
scribed and I have observed that if you follow the instructions about taking the medication
then you have no problem. (FDG 2)
The participants also revealed that they attended adherence counselling sessions at the
clinic prior to initiating the treatment. They suggested that a minimum of two (2) counselling
sessions with a trained adherence counsellor enhanced their knowledge about the medication
and the relevant instructions to follow. It was also mandatory to attend the counselling sessions
with an adherence monitor (family member or friend) who would ensure that support for
adherence was provided.
Familiarity with medication regimen. Although participants were unable to mention the
name of the medications, they had no problem identifying the medication and how these were
to be taken. Most participants used the colour, shape and size, of medication to follow their
medication regimen. Participants’ regimen was mostly once daily (QD) or twice daily (BID);
and they had a pill or two to take in the morning, evening, or both morning and evening.
There were no complaints of pill burden–that is, the high number of pills taken on a regular
basis, which could deter participants from taking their medication.
Some of the participants acknowledged that the dosing regimen was changed during the
course of treatment; but this did not affect their medication adherence. The side effects of drug
and type of brand in stock necessitated the regimen changes; however, adherence to treatment
was not affected by these modifications.
Initially, some were twice daily dosing and once daily. Later it was changed again. Currently,
the medication I have I take 2 in the morning and 1 at night. (P1)
Field information revealed there were diverse brands of the ARVs. While some of the ARVs
were combined to a single dose, others were not; and therefore, the number of pills and dosing
varied. No matter the change in medication, participants were cognizant of the benefits they
derived from taking the ARV’s and persisted in taking their medications.
Benefits of ART as a reason for adherence. The motivation for adherence was affected
by the benefits of ART. Some participants, after comparing their present state of health with
their past (prior to being put on ARVs), remarked that the medication was helpful. They
described the medication as a “source of energy” for them to be able to go about their daily
activities. Some acknowledged the action of the ARV as being able to fight the activities of the
virus, thereby improving their general health.
Just as my colleague mentioned, the medication that we take reduces the activity of the virus
and gives us energy. Since I started taking the medication, I feel healthier and there is a differ-
ence in my energy levels. I feel very strong. I take my medication religiously because I know
how taking it has helped me. (FGD 2)
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Participants recognised that taking the medication consistently was a catalyst for maintain-
ing good health while living with HIV.
Access to food promotes adherence. Some participants suggested that access to food pro-
moted their adherence to the ARVs. They mentioned experiencing undesired side effects of
the ARVs (weakness and dizziness) when they took their medication without food. Partici-
pants added that eating a balanced diet also contributed to their recovery. A participant noted:
The part about eating well before taking the medication is not a joke. The medication needs
food. In the evening if you take the drug after eating, then it is able to work well. But if you
haven’t eaten before taking it, then you will be in serious trouble. You might feel like someone
who took alcohol or ‘wee’ [Marijuana]. (FGD 1)
Participants of the focus group discussions mentioned that eating well before taking the
medication was very important. Some noted that failure to eat before taking the medication
worsened the side effects of the treatment. Access to food and eating the right combination of
food, in their view, contributed to minimising treatment side effects, such as weakness, and
ensured that their treatment regimen was not stopped or skipped. One participant argued that
failing to eat before taking the medication could result in death.
Fear of death motivates adherence. Due to previous observations of how others died,
three (3) participant opined that the fear of dying was a strong motivator for adherence to
treatment. Recounting the events characterising the diagnosis of HIV, some of the participants
appreciated that adhering to treatment had improved their health. Failure to adhere to treat-
ment was perceived as a risk for poor health and death; hence, participants strictly adhered to
the treatment regimen.
. . .if it is time for the medication, and you don’t take your medication the disease will recur
and if that happens it can kill you. . .Because you will be there and the illness will come back
and if you are not careful you will die and leave your children. . .(P3)
I think the way I felt and was seriously sick I was afraid that I will die so it gave me the moti-
vation to be more conscious about my medication. (P1)
One participant comparing himself to other PLWHIV, noted that his health status was bet-
ter. He attributed his good health to his willingness to adhere to treatment in order to mini-
mise the risk of dying. Other comments were:
I want to make it clear that if you have this illness then you are not part of the living you are
as good as dead, but with the medication you have a hope of living and therefore you must
take it unless you want to die. (FGD 1)
A focus group participant mentioned that HIV seemed like a death sentence; but with the
medication, the hope of survival was better. Another participant mentioned that people who
worry about their condition tend to miss their medication. Addressing the fear of death was
seen as a positive step to improving adherence and avoiding the consequences. The desire to
live and experience good health motivated adherence to ART among participants.
Pill mobility enhances adherence. The medication times and schedules of participants
varied. However, participants mentioned alternative methods of adhering to treatment despite
the disruption of their medication regimen by other activities. Carrying pills when travelling
or going out was an example of such an alternative. One participant noted:
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I always make it a point that it is always on me. Wherever I am going it’s in my purse. At least
it’s either you just cut a piece of it, you wrap it somewhere and put it in your bag so that you
take . . .I think it is working but they should bring something that we don’t have to take or
carry all the time so you don’t forget maybe an injection or something else. (P1)
Participants of focus group discussion three (3) identified that going out without their med-
ication on their person contributed to delaying the medication administration. However, par-
ticipants also suggested that pill mobility came with a risk of being noticed in public with the
ARVs. Nevertheless, a participant mentioned that she sometimes takes her ARVs on a bus
while travelling.
Status disclosure (Transparency and openness). Participants’ responses suggested that
adherence to treatment required transparency about one’s HIV status, since it enabled
PLWHIV to receive support from family members and significant others. However, only a few
participants mentioned they could take their medication if others were looking at them.
. . .recently I had to inform my younger brother because when I went to his room his wife was
pregnant and I saw some of my drug on the table in their room. I called him aside and cau-
tioned him about the way he had left the drug ‘we don’t put it like that on a table’ because if
someone who is taking it sees it he or she would know (referring to knowing HIV status). So he
asked me; do you know what it is? I told him that if I did not know I would not say so. I took
him to my room and showed my medication to him before he believed me. (P6)
The participant’s transparency about her HIV status and ARV created the opportunity for
her brother to disclose his wife’s HIV positive status and active ART. His wife was willing to
have her status disclosed to close relations. Transparency about their status demonstrated that
they had overcome the barrier of stigma to reduce their risk of non-adherence.
Voice calls promote adherence. Evaluating the experiences with alarm use, text messages,
and voice calls, as adherence support measures revealed mixed feelings among participants.
There was generally a preference for voice calls as the calls were made in an indigenous lan-
guage, had a greater personal and emotional component, and were also more interactive than
text messages. Some participants noted that the calls they received at month three (3) and
month six (6) reminding them to turn up for appointments were useful. They advocated that
the intervention should be included in the care strategy because they had problems remember-
ing appointment dates. Some of the comments were:
I really like the calls that coincided with the clinic days because I get to be reminded about my
clinic appointment. (FDG 2)
You also encouraged us to use the alarm on the phone to remind us take our medication.
Sometimes I received messages and calls as well. I feel that the phone call is good. (FDG 2)
The way you called us to come to the clinic is the one I like especially when we finish you give
us transport that one is very good. (P5)
One participant noted that voice calls offered good opportunities for reinforcing adherence
counselling and motivating retention in treatment.
Adherence behaviour inhibitors
Although most of the participants indicated they were adherent to treatment, some mentioned
instances of nonadherence. They suggested that adherence is inhibited by situations such as
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forgetting pills, religious beliefs, oversleeping, secrecy, and wasting time. The evaluation of the
mobile phone intervention suggested that text messages were not preferred because of the
associated risk of HIV status exposure.
Forgetfulness. Some participants reported forgetting to take their medication while oth-
ers admitted forgetting their appointment schedules.
I think the doctors themselves know that some people could forget the follow up date. I some-
times miss the date, but once I notice my medication is reducing, I go back to the clinic for
refill. You have to keep tracking the clinic days otherwise the date would elapse before you
realize it. If you do not exceed one week then you could still have medications, because they
always make sure that you receive medication in excess of your reporting day. (P2)
In spite of the risk of forgetfulness, a focus group discussion one (1) participant mentioned
that the mobile phone intervention helped to keep track of time to avoid missing a dose. Mak-
ing reference to what could account for forgetfulness and missing pills among PLWHIV on
ARVs, some participants suggested that worrying about the illness was a key factor.
I may forget, so the phone has to be with me always so that I can check the time. (FGD 1)
It is when you are worried about the illness and see it as a problem that you are likely to forget.
(P3)
Religious beliefs. Some participants indicated that, although taking the medication was
important, some people may be non-adherent to their treatment because of instructions from
religious leaders, such as pastors or priests. They gave accounts of other PLWHIV dying
because they discontinued taking their medication and pursued religious activities, such as
going to prayer camps for prayers, fasting, and deliverance sessions—a form of religious prac-
tice considered as an exorcism of evil disease-causing spirits.
Sometimes some of them abandoned their medication claiming that their pastors have asked
them to come to the prayer camp for fasting. . . Someone was asked by the pastor to come for
fasting and deliverance and she has lost her life through that. (P3)
Another bad thing is that most people living with HIV listen to their pastors when they visit
prayer camps, who advise them not to take the drugs. They therefore expect to be healed from
the prayers which eventually make them weaker and weaker after refraining from taking the
medications. God is indeed able, but stopping the medicine is inexcusable in this regard. (P2)
Some participants also expressed concerns about seeking religious support without adher-
ing to the ARVs. They clarified that they adhered to the ARVs even while seeking a cure for
HIV through religion. They argued that priests who convince PLWHIV to stop treatment
were also contributing to the problem of non-adherence. Beyond patient education on adher-
ence, participants did not state what else could be done to curtail the priests’ practice.
Nondisclosure of status (Secrecy). Some participants reported physically hiding to take
their medication, in order to avoid stigma. This was because they had not disclosed their HIV
status to anyone. Participants suggested that keeping the HIV status secrete spared them from
negative comments and stares. Participants who were parents did not disclose their HIV status
to their children especially if their children were of a young age (adolescents and younger). A
strategy commonly used by some of the participants was changing the pill bottles to disguise
their medication.
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I have poured my medicine in a vitamin bottle, so in case I am taking it you would not know
which medicine I am taking. . .If you are taking medicine every day for people to see you
would subject yourself to unnecessary questions. So it is better to keep everything to yourself
and hide before taking it. You don’t have to expose your medicine anyhow. (FGD 3)
Participants did not indicate that hiding to take medication prevented them from taking
the medication. Nevertheless, the secrecy associated with HIV and its treatment has the poten-
tial to affect adherence behaviour. When significant others are aware of the PLWHIV’s status,
they might provide support with reminders to take treatment, accompany the PLWHIV to
hospital for appointments and provide emotional support.
Waiting time. Some of the participants were concerned about the waiting time at the hos-
pital during clinic visits for medication refills. They argued that long waiting hours at the clinic
and the pharmacy could discourage them from returning for follow-up appointments.
Sometimes when you come to the clinic you spend the whole day here waiting. From this place
you have to go and wait at the pharmacy as well. (P5)
Some of the participants admitted they were offered preferential treatment when they fabri-
cated excuses as to why they should be served earlier. Still, they were uncomfortable because of
how the other people seeking medical attention may have felt each time they were permitted to
jump the queue.
Sleeping. Two (2) of the participants pointed out in their narratives that they sometimes
overslept and, as a result, missed the exact time their next medication dose was due. Partici-
pants in the focus groups agreed that sleep sometimes delayed their medication, noting that:
Well, I wasn’t taking it religiously because sometimes I oversleep and my time will pass and if
that happens it affects me. (P1)
The introduction of the mobile phone alarm was beneficial in addressing the problem of
sleep. Participants mentioned that they kept the phone close to them so that the alarm would
wake them up to take their medication when they overslept.
Discussion and conclusion
Patients suggested that when the medication regimen was simple, pill burden was minimal
and dosing time was convenient, which promoted adherence. These findings are consistent
with other studies [6–8,18] on factors influencing adherence to treatment. Generally, motiva-
tion to adhere was linked to the benefits of ART and the consequences of non-adherence. The
primary benefit of treatment was in the improvement in health status as reported by Portelli
et al. [11]. Starks et al. [9] identified that the desire to live motivated adherence; hence, partici-
pants were willing to take measures that facilitated adherence, including carrying their pills on
their person. However, there were deliberate efforts that ensured the pills were disguised to
avoid suspicion and stigma [9,11,18].
The contrast between the use of secrecy in dealing with perceived stigma and the role of open-
ness in promoting ART adherence requires further investigation. We need to understand and
address how transparency about HIV status promotes support from spouses, family, and friends,
as well as measures for improving HIV status disclosure. There is evidence that affirms that
adherence is promoted when HIV status is disclosed because PLWHIV can receive support.
Food was considered an energy buffer that addressed medication side effects, such as body
weakness and dizziness. It is, therefore, an important aspect of treatment adherence [19]. Food
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insecurity is noted as one of the inhibitors affecting treatment adherence. Accordingly, nutri-
tional support has been used as an adherence intervention; and the WHO [1] has recom-
mended supporting the treatment of PLWHIV on treatment with food provisions.
Adherence inhibitors, such as forgetting medication times and sleeping through doses,
could be resolved by using mobile phone interventions (alarms). Other studies support how
measures such as alarms and text messages have addressed non-adherence [20,21]. However,
certain religious beliefs promote non-adherence. For example, the belief that religious prac-
tices like prayers and deliverance (exorcism) could cure HIV encourages PLWHIV to seek
solutions from religious leaders. Future interventions need to target religious leaders in order
to build their knowledge on HIV/AIDS, its causes and evidence-based treatment options. This
may promote early referral of PLWHIV to appropriate health centres for medical attention
prior to or while religious solutions are sought.
Theoretical interpretation of study outcome from the perspectives of behavioural learning
suggests that there are internal and external antecedents explaining adherence behaviour and
consequences [22]. The findings revealed personal determination (internal antecedent) precip-
itated adherence, while the use of the mobile phone (external antecedent) moderated behav-
iour. The consequence of adhering to the treatment was the benefit derived from the
treatment. In understanding these factors, measures for improving adherence promoters and
delimiting adherence inhibitors are key in sustaining adherence behaviour.
An elaborate context of describing adherence behaviour in this study is the application of
the theory of reasoned action. The theory postulates that behaviour is controlled by individu-
als’ intention, which predicts behaviour [23]. The intention to adhere depends on behavioural
beliefs, perceived norms, and control. Participants’ attitude towards adherence was informed
by the belief that making a personal decision to take the medication was important. Partici-
pants acknowledged the benefit of the treatment and how it improved their health; hence,
their willingness to take their medication. Nevertheless, they were cognizant of the possibility
of missing pill times; therefore, they embraced other measures such as alarms, text messages,
and voice calls to achieve the desired outcome.
Healthcare professionals working with PLWHIV need to recognise that this population has
high levels of motivation to adhere to treatment. Facilitating the development of adherence goals,
supporting patients with regular counselling, and providing follow-up care are practical measures
that can further promote treatment adherence. There is a need to explore other mechanisms that
will reduce clinic waiting time, such as appointment scheduling. Appointment scheduling should
be for specific dates and times, in order to reduce waiting times in the health care facilities.
Generally, qualitative studies rely on data saturation in determining the sample size. Never-
theless, additional interviews could have provided more depth for some of the key issues
explored, including the influence of religious belief, status disclosure, and access to food on
adherence behaviour. The integration of interviews and focus group discussions in presenting
the findings may be critiqued by other qualitative researchers as unsuitable. In this study,
trained PLWHIV volunteered as interviewers and were supervised by the principal investiga-
tor (GD) to conduct some interviews. Their involvement in data collection may have been
associated with a risk of interviewer bias. However, the volunteers’ familiarity with the partici-
pants appeared to have contributed to participants’ open discussion of the issues related to the
promoters and inhibitors of treatment adherence.
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